Canada markets closed

NLS Pharmaceutics AG (NLSP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6200-0.0765 (-10.98%)
At close: 03:59PM EDT
0.6133 -0.01 (-1.08%)
After hours: 07:58PM EDT

NLS Pharmaceutics AG

The Circle 6
Zurich 8058
Switzerland
41 44 512 21 50
https://nlspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Alexander Zwyer M.B.A.Pres, CEO & DirectorN/AN/A1969
Mr. Chad C. Hellmann M.B.A.Chief Financial OfficerN/AN/AN/A
Mr. Eric Konofal M.D., Ph.D.Chief Scientific OfficerN/AN/A1967
Dr. Christian C. Wenger Dr. iur., L.L.M., LL.M., Ph.D.Gen. CounselN/AN/A1964
Ms. Sharon KeysHead of Regulatory AffairsN/AN/AN/A
Dr. George Apostol M.D.Chief Medical Officer and Global Head of R&DN/AN/A1973
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.

Corporate Governance

NLS Pharmaceutics AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.